submit to the journals

Immunotherapy Journal Articles, Videos And Insights

Immunotherapy:FEATURED Articles

flipper_slider

Immunotherapy: Latest Articles

Immunotherapy: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Insight
Realising the Promise of Cell Therapy – The Automated in-house CAR T cell Manufacturing System James Gilbart
Touch Medical Communications, Goring on Thames, UK

Immunotherapy:FEATURED VIDEOS

Editor's choice

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for investigating radical resection of metastases followed by sorafenib in advanced renal cell carcinoma? (0:11) 2. Could you tell us a little about the RESORT study design? (1:15) 3. What were the findings of the study? (1:50) 4. Why do you think sorafenib has no effect on relapse-free survival? (3:17) 5. What will be the next steps in this clinical investigation? (4:06) Speaker disclosures: Giuseppe Procopio serves on the advisory board for Bayer, Bristol-Myers Squibb, Ipsen, Novartis and Pfizer. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Part 1 of 2 – In our interview with Dr Ajjai Alva, he discusses the importance of histology and performance status in selecting patients for high dose interleukin-2 therapy. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017

Immunotherapy:Latest Videos

Video List based on Category on Node Page

Latest Videos

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for...
Part 2 of 2 - Dr Ajjai Alva explains checkpoint inhibitors and discusses their use in combination with IL-2 for patients who do not respond to checkpoint inhibitors alone. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Part 1 of 2 – In our interview with Dr Ajjai Alva, he discusses the importance of histology and performance status in selecting patients for high dose interleukin-2 therapy. Filmed at The American Society of Clinical Oncology (ASCO) meeting, 2017
Ahmad Awada, from our editorial board, discusses the current and future developments in immunotherapy.
Frédérique Penault Llorca discusses the latest research into biomarkers and the predictability of immunotherapy response.
Part 2 of 2 – Dr Marc Peeters, from our European Editorial Board, explains the move from treating patients with BRAF-targeting drugs, to using combination therapy to target the EGFR pathway in BRAF-mutant mCRC. He also discusses the BEACON CRC study, which uses this combination of binimetinib,...

LATEST TWEETS

Conference Highlights